Ingelheim/Cologne, 30 November 2017
Boehringer Ingelheim, one of the world‘s leading research-driven pharmaceutical companies, has signed a global license agreement to use the “enterprise:inmation” industrial information management system from inmation Software GmbH, a technology leader in real-time information management solutions for large scale industries. The license agreement will enable Boehringer Ingelheim to create uniform real-time data infrastructure at all of its production facilities around the globe. Prior to conclusion of the contract Boehringer Ingelheim has tested the software in an in-depth evaluation for several months. In addition, as one of the first users from the pharmaceutical industry, Boehringer Ingelheim will join the advisory board of inmation Software to help further develop the management system to continue to meet the advanced needs of the industry.
The enterprise:inmation industrial information management system enables businesses to acquire system, process and production data in real-time and make them available model-based. It is infinitely scalable, both in terms of data capacity and number of global locations, simply leveraging existing data sources from any location. This enables the integration of all systems with a digital interface such as ERP, MES, DAQ, SCADA, DCS or PLC into a global real-time data backbone. As a result the data from heterogenous systems is pulled into a homogenous database that enables users to access the relevant information required at the appropriate level of detail web-based from anywhere with any device. Once the system is installed, it offers fully automated and centrally controlled software updates without burdensome version migration projects.
“enterprise:inmation is a great way to further advance the digital integration of our pharmaceutical production lines, to reduce costs and make our systems fit for the future. Boehringer Ingelheim and inmation Software are two global leaders based in Germany – this is the beginning of a perfect partnership”, says Klaus Fickinger, Head of Automation Pharma & Data Integrity at Boehringer Ingelheim.
The agreed further development of enterprise:inmation will concentrate on the compatibility of lean TCO and the need of software validation within the pharmaceutical industry. “This industry is strictly regulated by guidelines such as Part 11 of the Food and Drug Administration (FDA) or Good Manufacturing Practice (GMP). These special requirements need to be matched with the strengths of our software, like the low total costs of ownership due to the high level of automation”, says Timo Klingenmeier, CEO of inmation Software GmbH. “Our new global license agreement with Boehringer Ingelheim is a great endorsement of our work so far and starts a strong partnership with a highly experienced partner within the regulated production process industry.”
About inmation Software:
Headquartered in Cologne, Germany, inmation Software GmbH is a global technology leader in real-time information management for the industry. The enterprise:inmation system helps companies create a real-time infrastructure for holistic monitoring of all acquired industrial data, reducing the total cost of ownership (TCO) while enhancing digital integration. The scalable software aligns to the customer’s needs and is able to integrate machinery and components independent of manufacturer – from micro-installations for a single host to enterprise-wide solutions with hundreds of systems globally.
The ever-growing client base consists of national and global leaders for numerous industries, including Chemicals, Oil & Gas, Energy & Utilities, Discrete Manufacturers and Special Machinery Builders. Working with both regional and international partners, inmation Software offers its expertise to all industries to help realize 360-degree integration and full enterprise control effectively and sustainably.
For more information, please visit: www.inmation.com.
About Boehringer Ingelheim:
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report.
For further information please contact:
Daniel Secker
Media Management
inmation Software GmbH
+49(0)221 168 144 16
E-mail: daniel.secker@inmation.com
Björn Oberhössel
Account Manager
Technical Publicity
+49(0)4181 968 098 30
E-mail: boberhoessel@technical-group.com